Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,959 | 117 | 98.7% |
| Education | $38.69 | 6 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Relypsa, Inc. | $735.46 | 33 | $0 (2019) |
| Amgen Inc. | $433.07 | 14 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $422.61 | 19 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $207.07 | 7 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $131.91 | 2 | $0 (2024) |
| NxStage Medical, Inc. | $130.81 | 2 | $0 (2018) |
| CALLIDITAS THERAPEUTICS US INC. | $116.11 | 2 | $0 (2022) |
| BAXTER HEALTHCARE | $100.00 | 1 | $0 (2018) |
| Mallinckrodt LLC | $97.81 | 5 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $84.58 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $239.73 | 2 | Amgen Inc. ($131.37) |
| 2022 | $298.86 | 10 | CALLIDITAS THERAPEUTICS US INC. ($116.11) |
| 2021 | $47.95 | 2 | Otsuka America Pharmaceutical, Inc. ($47.95) |
| 2020 | $120.12 | 7 | E.R. Squibb & Sons, L.L.C. ($29.85) |
| 2019 | $763.01 | 35 | Relypsa, Inc. ($216.07) |
| 2018 | $874.76 | 31 | Relypsa, Inc. ($288.39) |
| 2017 | $653.20 | 36 | Relypsa, Inc. ($231.00) |
All Payment Transactions
123 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $108.36 | General |
| Category: Cardio-renal | ||||||
| 04/17/2024 | Amgen Inc. | Aranesp (Biological) | Food and Beverage | In-kind items and services | $131.37 | General |
| Category: Nephrology | ||||||
| 12/14/2022 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: NEPHROLOGY | ||||||
| 12/07/2022 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $93.98 | General |
| Category: Nephrology | ||||||
| 10/13/2022 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $33.31 | General |
| Category: Hyperkalemia | ||||||
| 10/06/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: Cardio-renal | ||||||
| 09/27/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/19/2022 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: Nephrology | ||||||
| 07/27/2022 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: NEPHROLOGY | ||||||
| 06/08/2022 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: Hyperkalemia | ||||||
| 05/23/2022 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $27.84 | General |
| Category: Nephrology | ||||||
| 05/16/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/08/2021 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: NEPHROLOGY | ||||||
| 08/19/2021 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: NEPHROLOGY | ||||||
| 08/11/2020 | Cumberland Pharmaceuticals, Inc. | Vaprisol Dextrose in Plastic Container (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Nephrology | ||||||
| 03/20/2020 | Ultragenyx Pharmaceutical Inc. | Cryvista (Drug) | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: XLH Metabolic Bone Disorder | ||||||
| 02/25/2020 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.04 | General |
| Category: Cardiovascular | ||||||
| 02/24/2020 | E.R. Squibb & Sons, L.L.C. | NULOJIX (Biological) | Food and Beverage | Cash or cash equivalent | $15.81 | General |
| Category: Immunology | ||||||
| 02/18/2020 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: NEUROLOGY | ||||||
| 02/11/2020 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: Hyperparathyroidism | ||||||
| 01/14/2020 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: NEPHROLOGY | ||||||
| 12/17/2019 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: Hyperkalemia | ||||||
| 11/19/2019 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: Hyperkalemia | ||||||
| 11/14/2019 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $106.29 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/12/2019 | OPKO Pharmaceuticals, LLC | Rayaldee (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: Hyperparathyroidism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 123 | 258 | $150,784 | $61,452 |
| 2022 | 8 | 483 | 1,023 | $448,729 | $164,453 |
| 2021 | 16 | 906 | 1,850 | $635,820 | $246,947 |
| 2020 | 16 | 1,258 | 2,415 | $641,983 | $262,570 |
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 46 | 162 | $116,316 | $47,388 | 40.7% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 23 | 35 | $20,930 | $8,634 | 41.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 36 | $5,832 | $2,336 | 40.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $4,248 | $1,706 | 40.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $3,458 | $1,389 | 40.2% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 67 | 326 | $247,168 | $95,524 | 38.6% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 56 | 92 | $57,809 | $22,782 | 39.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 136 | 218 | $59,876 | $15,186 | 25.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 108 | 249 | $37,396 | $14,752 | 39.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 46 | 46 | $19,172 | $7,643 | 39.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 34 | $13,133 | $3,022 | 23.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 23 | 25 | $7,105 | $2,806 | 39.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 33 | $7,070 | $2,738 | 38.7% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 72 | 348 | $256,704 | $102,772 | 40.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 181 | 320 | $86,651 | $32,596 | 37.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 166 | 476 | $70,385 | $28,873 | 41.0% |
| 90966 | Home dialysis services per month, patient 20 years of age or older | Office | 2021 | 12 | 84 | $50,464 | $15,518 | 30.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 87 | 91 | $37,350 | $14,911 | 39.9% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 37 | 45 | $27,783 | $11,073 | 39.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 59 | 74 | $28,143 | $11,021 | 39.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 58 | 62 | $17,241 | $6,814 | 39.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 50 | 65 | $13,560 | $5,625 | 41.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 19 | 19 | $8,598 | $3,599 | 41.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 26 | 34 | $8,492 | $3,322 | 39.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time per calendar month | Office | 2021 | 19 | 80 | $6,531 | $2,606 | 39.9% |
About Dr. Roy Marcus, M.D
Dr. Roy Marcus, M.D is a Nephrology healthcare provider based in Upland, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245278084.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roy Marcus, M.D has received a total of $2,998 in payments from pharmaceutical and medical device companies, with $239.73 received in 2024. These payments were reported across 123 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($2,959).
As a Medicare-enrolled provider, Marcus has provided services to 2,770 Medicare beneficiaries, totaling 5,546 services with total Medicare billing of $735,422. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Location Upland, PA
- Active Since 06/03/2006
- Last Updated 07/26/2012
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1245278084
Products in Payments
- Veltassa (Drug) $793.39
- JYNARQUE (Drug) $356.43
- Parsabiv (Biological) $203.05
- LOKELMA (Drug) $169.53
- Aranesp (Biological) $155.65
- Kerendia (Drug) $131.91
- System One (Device) $130.81
- TARPEYO (Drug) $116.11
- Renal - Chronic (Device) $100.00
- ACTHAR (Biological) $97.81
- XARELTO (Drug) $84.58
- SAMSCA (Drug) $77.97
- NULOJIX (Biological) $69.13
- Rayaldee (Drug) $62.52
- Parsabiv (Drug) $52.03
- AFINITOR (Drug) $49.13
- FARXIGA (Drug) $37.54
- FABRAZYME (Drug) $35.83
- FERAHEME (Drug) $34.72
- ELIQUIS (Drug) $25.51
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Upland
Chike Okechukwu, M.d, M.D
Nephrology — Payments: $22,561
Dr. Nima Naimi, D.o, D.O
Nephrology — Payments: $2,060
Mary Bui
Nephrology — Payments: $1,574
Jin Wang, M.d, M.D
Nephrology — Payments: $1,562
Minna Huang, M.d, M.D
Nephrology — Payments: $1,337
Sat Arora, M.d, M.D
Nephrology — Payments: $365.33